Drugs / HZ/su vaccine
HZ/su vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05966090 | Jul 2023 → Feb 2024 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HZ/su vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05966090 ↗ |
| Known as | Herpes Zoster recombinant subunit vaccine, Shingrix | “Herpes Zoster recombinant subunit vaccine, Shingrix” NCT05966090 ↗ |
| Known as | RZV | “AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV)” PMID 42054374 ↗ Apr 2026 |
| Modality | Vaccine | “AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV)” PMID 42054374 ↗ Apr 2026 |
| Route | Intramuscular | “given intramuscularly” NCT05966090 ↗ |